Current Insights Into the Impact of Dihydropyrimidine Dehydrogenase Deficiency in Patients Receiving Treatment With 5-Fluorouracil

Clinical Advances in Hematology & Oncology Volume 14, Issue 7, July 2016 Robert B. Diasio, MD William J. and Charles H. Mayo Professor Director, Mayo Clinic […]

Novel Approaches to Delivering Value in Oncology Drugs

Clinical Advances in Hematology & Oncology April 2016, Volume 14, Issue 4 Steve Miller, MD Senior Vice President & Chief Medical Officer Express Scripts St Louis, […]

The Effect on Drug Development of the National Cancer Institute’s Cancer Therapy Evaluation Program

Clinical Advances in Hematology & Oncology March 2016, Volume 14, Issue 3 James Zwiebel, MD Chief, Investigational Drug Branch Cancer Therapy Evaluation Program National Cancer Institute […]

Casting Doubt on the Scientific Utility of Post-treatment Biopsies in Phase 1 Trials

Clinical Advances in Hematology & Oncology February 2016, Volume 14, Issue 2 Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine Director, Center for Personalized Therapeutics […]

The Impact of Value-Based Insurance Design on Oncology Drugs

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1 A. Mark Fendrick, MD Professor, Internal Medicine Director, Center for Value-Based Insurance Design […]

The Current and Future Applications of Immunopharmacogenomics

Clinical Advances in Hematology & Oncology December 2015, Volume 13, Issue 12 Yusuke Nakamura, MD, PhD Professor of Medicine Departments of Medicine and Surgery The University […]

The Benefits and Drawbacks of Biosimilars

Bruce N. Cronstein, MD Professor of Medicine Department of Medicine Department of Biochemistry and Molecular Pharmacology Department of Pathology New York University School of Medicine New […]

The Value and Effectiveness of Angiogenesis Inhibitors for Colorectal Cancer

Alan P. Venook, MD The Madden Family Distinguished Professor of Medical Oncology and Translational Research School of Medicine University of California, San Francisco H&O What […]

Novel Drug Targets in Acute Leukemia

Clinical Advances in Hematology & Oncology August 2015, Volume 13, Issue 8 Wendy Stock, MD Professor Section of Hematology/Oncology Director, Leukemia Program University of Chicago […]

Second-Generation ALK Inhibitors

Clinical Advances in Hematology & Oncology July 2015, Volume 13, Issue 7 Hiroyuki Mano, MD, PhD Professor Department of Cellular Signaling Graduate School of Medicine […]

MET as a Drug Target

Volume 13, Issue 6 June 2015 Ravi Salgia, MD, PhD Professor of Medicine Director, Thoracic Oncology Program Vice Chair, Translational Sciences Department of Medicine, Section of […]

PARP Inhibitors in Ovarian and Other Cancers

Clinical Advances in Hematology & Oncology May 2015, Volume 13, Issue 5 Ruth Plummer, MA, BMBCh, DPhil, MD, FRCP Professor of Experimental Cancer Medicine, Newcastle University, Newcastle […]

The National Cancer Institute’s Experimental Therapeutics Clinical Trials Network

Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 S. Percy Ivy, MD, Associate Chief, Cancer Therapy Evaluation Program, Investigational Drug Branch, Division of Cancer Treatment […]

Redefining Dose-Limiting Toxicity

Clinical Advances in Hematology & Oncology February 2015, Volume 13, Issue 2 Sophie Postel-Vinay, MD, PhD, Drug Development Department, Institut Gustave Roussy, Villejuif, France H&O How are […]

Use of Predictive Biomarkers in Phase 2 Trials

Clinical Advances in Hematology & Oncology January 2015, Volume 13, Issue 1 Janet E. Dancey, MD, Professor, Department of Oncology, Director, NCIC Clinical Trials Group, Queen’s University School […]

What Is the Role of Journalists in Distinguishing Hype From Reality?

Clinical Advances in Hematology & Oncology December 2014, Volume 12, Issue 12 Paul Goldberg, Editor and Publisher, The Cancer Letter, Washington, DC H&O What are the most important traits […]

Translational Research in the National Cancer Institute’s Cooperative Groups

Clinical Advances in Hematology & Oncology November 2014, Volume 12, issue 11 W. Fraser Symmans, MD, Professor and Director of Research Operations, Department of Pathology, University of Texas […]

Unleashing the Power of Preemptive Pharmacogenomics

Clinical Advances in Hematology & Oncology October 2014, Volume 12, Issue 10 Peter H. O’Donnell, MD Assistant Professor of Medicine, University of Chicago, Chicago, Illinois H&O What […]

The Promise of Genomics-Based Drug Repurposing

Clinical Advances in Hematology & Oncology September 2014, Volume 12, Issue 9 Joel Dudley, PhD, Assistant Professor of Genetics and Genomics Sciences, Director of Biomedical Informatics, Icahn […]

Incorporating Biomarkers Into Drug Labeling

Clinical Advances in Hematology & Oncology August 2014, Volume 12, Issue 8 Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine, Director, Center for Personalized Therapeutics, Associate Director […]